Balancing Intellectual Property and Humanity: Public Policy and the Patentability of Pharmaceuticals in Canada
The Canadian Intellectual Property Review (CIPR) is a double-blind peer reviewed journal. It is sent to over 1,800 IPIC members at no cost and can be purchased by non-members for a fee. If you would like to browse the articles included in the CIPR, please consult our database below.
Any author, member or non-member can submit an article for consideration in the CIPR. The CIPR Editorial Board welcomes both short pieces (2,000 to 5,000 words) that may be included in the Notes section of the issue or longer, more in-depth articles. The maximum length of articles, including references, is 20,000 words. Articles may be submitted in French or English. Each article should be accompanied by a 150-word abstract.
All submissions undergo a double-blind review process: the reviewers are not given the authors' identities and the identities of the reviewers are shielded from the authors. Additionally, articles submitted must be original and must not have been previously published elsewhere.
If you would like to submit an article for an upcoming issue of the CIPR please contact admin@ipic.ca.
Canadian Intellectual Property Review
Share
Balancing Intellectual Property and Humanity: Public Policy and the Patentability of Pharmaceuticals in Canada
Issue: Volume 25 no 2
Author(s): Steve Seiferling
Abstract:
The concept of intellectual property seeks a balance between proprietary rights associated with patentable inventions and the free flow of useful, affordable inventions. In the context of pharmaceuticals, there is a public policy argument with respect to global (and domestic) health concerns—specifically, the affordable and accessible treatment and prevention of disease through pharmaceutical treatment—that the public interest would benefit from the elimination of patent protection over pharmaceuticals. In Canada, an argument can be made for the elimination of pharmaceutical patent rights, based on health concerns, and the prevention and treatment of disease. However, currently, there are both practical and legal bars to eliminating patent rights. Canada must therefore look at alternative solutions for affordable access to medications. Two such solutions are proposed in this paper: first, the elimination of new-use patents would limit the access to extended protection for pharmaceuticals after the patent over the drug itself has expired; second, a compulsory licensing scheme would balance the economic interests of pharmaceutical patent holders with the desire of generic companies to enter the drug market and offer competitive prices for pharmaceuticals. Both solutions are steps in the right direction toward timely, affordable access to useful pharmaceuticals in Canada.
